Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report

Human epidermal growth factor receptor 2 (HER2) mutation in non-small cell lung cancer (NSCLC) is an oncogenic driver that possibly becomes a druggable target to HER2-targeted therapy. The benefit of HER2-targeted therapy is much less defined especially in eastern populations. We provide evidence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Cheol Kyu, Hur, Jae Young, Choi, Chang-Min, Kim, Tae-Ok, Cho, Hyun-Ju, Shin, Hong-Joon, Lim, Jung-Hwan, Choi, Yoo-Duk, Kim, Young-Chul, Oh, In-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729642/
https://www.ncbi.nlm.nih.gov/pubmed/29215816
http://dx.doi.org/10.3346/jkms.2018.33.e7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729642/
https://www.ncbi.nlm.nih.gov/pubmed/29215816
http://dx.doi.org/10.3346/jkms.2018.33.e7

Ejemplares similares